61 related articles for article (PubMed ID: 30765148)
1. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
[TBL] [Abstract][Full Text] [Related]
3. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jandial DA; Brady WE; Howell SB; Lankes HA; Schilder RJ; Beumer JH; Christner SM; Strychor S; Powell MA; Hagemann AR; Moore KN; Walker JL; DiSilvestro PA; Duska LR; Fracasso PM; Dizon DS
Gynecol Oncol; 2017 May; 145(2):236-242. PubMed ID: 28341300
[TBL] [Abstract][Full Text] [Related]
4. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
5. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract][Full Text] [Related]
6. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Lesnock JL; Farris C; Krivak TC; Smith KJ; Markman M
Gynecol Oncol; 2011 Sep; 122(3):473-8. PubMed ID: 21665250
[TBL] [Abstract][Full Text] [Related]
7. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Grabosch S; Tseng G; Edwards RP; Lankes HA; Moore K; Odunsi K; Vlad A; Ma T; Strange M; Brozick J; Lugade A; Omilian A; Bshara W; Stuckey AR; Walker JL; Birrer M
Gynecol Oncol; 2017 Jul; 146(1):137-145. PubMed ID: 28483269
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Havrilesky LJ; Secord AA; Darcy KM; Armstrong DK; Kulasingam S;
J Clin Oncol; 2008 Sep; 26(25):4144-50. PubMed ID: 18757328
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.
Nagao S; Fujiwara K; Yamamoto K; Tanabe H; Okamoto A; Takehara K; Saito M; Fujiwara H; Tan DSP; Yamaguchi S; Adachi S; Kikuchi A; Hirasawa T; Yokoi T; Nagai T; Sato T; Kamiura S; Fujishita A; Loong WW; Chan K; Syks P; Olawaye A; Ryu SY; Shigeta H; Kondo E; Yokoyama Y; Matsumoto T; Hasegawa K; Enomoto T
NEJM Evid; 2023 May; 2(5):EVIDoa2200225. PubMed ID: 38320049
[TBL] [Abstract][Full Text] [Related]
11. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
12. Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.
Lietz AP; Weaver DT; Melamed A; Rauh-Hain JA; Wright JD; Wright AA; Knudsen AB; Pandharipande PV
PLoS One; 2019; 14(9):e0222828. PubMed ID: 31539415
[TBL] [Abstract][Full Text] [Related]
13. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
14. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Farley JH; Brady WE; O'Malley D; Fujiwara K; Yonemori K; Bonebrake A; Secord AA; Stephan JM; Walker JL; Nam JH; Birrer MJ; Gershenson DM
Gynecol Oncol; 2022 Dec; 167(3):423-428. PubMed ID: 36244829
[TBL] [Abstract][Full Text] [Related]
15. Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
Martin AL; Colin-Leitzinger CM; Sinha SK; Chern JY; Peres LC
Br J Cancer; 2023 Jun; 128(12):2236-2242. PubMed ID: 37024666
[TBL] [Abstract][Full Text] [Related]
16. A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.
Defferrari C; Campora S; D'Amico M; Piccardo A; Biscaldi E; Rosselli D; Pasa A; Puntoni M; Gozza A; Gennari A; Zanardi S; Lionetto R; Bandelloni M; Decensi A
J Ovarian Res; 2012 Jun; 5(1):17. PubMed ID: 22732001
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Bui N; Kamat N; Ravi V; Chawla S; Lohman M; Ganjoo KN
Rare Tumors; 2018; 10():2036361318771771. PubMed ID: 29760870
[TBL] [Abstract][Full Text] [Related]
18. The use of intraperitoneal chemotherapy for advanced ovarian cancer - The experience of a tertiary referral centre.
Foster L; Girgis C; Kirby A; Harnett P; Brand A
Aust N Z J Obstet Gynaecol; 2023 Nov; ():. PubMed ID: 37994114
[TBL] [Abstract][Full Text] [Related]
19. The Role of Intraperitoneal Carboplatin as Consalidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review.
Mousavi A; Karimi-Zarchi M; Behtash N; Modares-Gilani M; Mokhtari-Gorgani M; Mehrdad N; Rouhi M; Anari PY
Int J Biomed Sci; 2016 Dec; 12(4):120-124. PubMed ID: 28190981
[TBL] [Abstract][Full Text] [Related]
20. Epithelial ovarian cancer: A case report.
Gao J; Fang H; Wang X; Wu L; Zhang R; Han Y
Exp Ther Med; 2014 Nov; 8(5):1535-1538. PubMed ID: 25289055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
